Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Cancer Treat Rev. 2019 Oct 28;81:101912. doi: 10.1016/j.ctrv.2019.101912

Fig. 3. TME modulation and promotion of anti-tumor immunity by regorafenib.

Fig. 3.

Several TME’s components promote an immune suppressive environment. Regorafenib modulates immuno-suppressive TME by blocking VEGFRs, TIE2, and CSF-1R, enhancing anti-tumor immunity. Abbreviations: CTL, cytotoxic T lymphocyte; DC, dendric cell; EC, endothelial cell; TAM, tumor-associated macrophage; TEM, TIE2-expressing monocyte/macrophage; TME, tumor microenvironment; Treg, regulatory T cell.